Clinical Trials Browser

Phase 1/2 × Breast Neoplasms × Lisaftoclax × Clear all

NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2 Suspended

Breast Neoplasms